Clinical Trial Update: 68Ga-PSMA PET/CT in Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating 68Ga-PSMA PET/CT for prostate cancer has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-PSMA PET/CT (68Ga-PSMA PET/CT imaging agent)

Snippet

Sponsor: University of Saskatchewan | Conditions: Prostate Cancer | Phase 3 | Status: SUSPENDED